Pivotal Phase 3 ARTEMIS Trial Data Demonstrates Consistent Safety and Efficacy of AR101 in Children and Adolescents with Peanut Allergy by mparnell | Jun 2, 2019 | Portfolio News
Aimmune Announces U.S. FDA Advisory Committee Meeting Date for AR101 for Peanut Allergy by mparnell | May 16, 2019 | Portfolio News
Poseida Therapeutics Receives US FDA Orphan Drug Destination for P-BCMA-101 for the Treatment of Multiple Myeloma by mparnell | May 13, 2019 | Portfolio News
Molecular Templates, Inc. Reports First Quarter 2019 Financial Results by mparnell | May 13, 2019 | Portfolio News
Kala Pharmaceuticals Reports First Quarter 2019 Financial Results by mparnell | May 9, 2019 | Portfolio News
